Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,058 recalls, newest first

Class III · Low risk

Acyclovir Tablets

Labeling: Incorrect or Missing Lot and/or Exp Date

Terminated Labeling / mix-up Heritage Pharmaceuticals Inc NDC 23155-227-01 D-0367-2021
Class I · High risk

BD ChloraPrep Hi-Lite Orange 26 mL Applicator

Defective Delivery System: An increase in complaints identified endcap being loose or falling off upon activation releasing glass shards containing the solution.

Terminated Packaging defect CareFusion 213, LLC NDC 54365-400-38 D-0373-2021
Class III · Low risk

Evrysdi (risdiplam)

Defective Container: complaints received regarding some incorrect press-in-bottle-adapters (PIBA), the incorrect PIBAs have a female instead of male fit so they cannot be used in combination with co-packed syringes.

Terminated Packaging defect Genentech Inc D-0357-2021
Class III · Low risk

Asenapine Sublingual Tablets

Incorrect Product Formulation; product was manufactured with the incorrect Art Cherry Flavor flavoring agent instead of Art Black Cherry Flavor flavoring agent

Terminated Other SigmaPharm Laboratories LLC NDC 42794-017-10 D-0380-2021
Class III · Low risk

Asenapine Sublingual Tablets

Incorrect Product Formulation; product was manufactured with the incorrect Art Cherry Flavor flavoring agent instead of Art Black Cherry Flavor flavoring agent

Terminated Other SigmaPharm Laboratories LLC NDC 42794-016-10 D-0379-2021
Class II · Moderate risk

Estradiol Transdermal System Delivers 0.0375 mg/day

Defective Delivery System: Out of specification for release rate testing and shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not stick well to the skin.

Terminated Packaging defect Noven Pharmaceuticals Inc NDC 68968-3437-8 D-0337-2021
Class II · Moderate risk

Minivelle (estradiol transdermal system)

Defective Delivery System: Out of specification for release rate testing and shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not stick well to the skin.

Terminated Packaging defect Noven Pharmaceuticals Inc NDC 68968-6675-8 D-0336-2021
Class II · Moderate risk

Oxygen

cGMP deviations

Terminated cGMP deviation Grace Healthcare Medical, Inc D-0355-2021
Class I · High risk

Thumbs up 7 Red 70K capsules

Marketed Without An Approved NDA/ANDA: Products found to contain undeclared tadalafil and/ or sildenafil and vardenafil making them unapproved drugs for which the safety and efficacy have not been established and therefore subject to recall.

Terminated Chemical / undeclared Ummzy, LLC D-0664-2021
Class I · High risk

Shogun-X capsules

Marketed Without An Approved NDA/ANDA: Products found to contain undeclared tadalafil and/ or sildenafil and vardenafil making them unapproved drugs for which the safety and efficacy have not been established and therefore subject to recall.

Terminated Chemical / undeclared Ummzy, LLC D-0663-2021
Class I · High risk

Krazy Night capsule

Marketed Without An Approved NDA/ANDA: Products found to contain undeclared tadalafil and/ or sildenafil and vardenafil making them unapproved drugs for which the safety and efficacy have not been established and therefore subject to recall.

Terminated Chemical / undeclared Ummzy, LLC D-0662-2021

Recalls by year